首页> 外文期刊>Cancer biology & therapy >Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines.
【24h】

Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines.

机译:骨桥蛋白而不是骨连接蛋白有利于胰腺癌细胞系的转移性生长。

获取原文
获取原文并翻译 | 示例
       

摘要

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in western countries and among the malignancies with the worst prognosis. Osteonectin and osteopontin, two proteins of the extracellular matrix, have been found to be upregulated in PDAC. In the present study the expression of osteopontin mRNA as determined in a panel of 14 human pancreatic cancer cell lines was significantly related to the growth of these cell lines in the liver of nude rats (p = 0.001); whereas osteonectin showed a trend of being negatively related to pancreatic cancer cell growth in vivo (p = 0.10). In an in vitro co-culture model of human Suit2-007 and rat AsML PDAC cells with rat hepatocytes, a clearly increased expression of OPN mRNA was found in the tumor cells. In addition, both downregulation of osteopontin with specific antisense oligonucleotides and treatment with exogenous rh-osteonectin were associated with reduced cell proliferation. In accordance with the latter finding downregulation of osteonectin was coupled with increased proliferation. This evidence supports a protumorigenic role of osteopontin and points to an antitumorigenic role of osteonectin in PDAC.
机译:胰腺导管腺癌(PDAC)是西方国家癌症相关死亡的第四大主要原因,也是预后最差的恶性肿瘤之一。已发现骨结合蛋白和骨桥蛋白是细胞外基质的两种蛋白,在PDAC中被上调。在本研究中,在一组14种人胰腺癌细胞系中确定的骨桥蛋白mRNA表达与裸鼠肝脏中这些细胞系的生长显着相关(p = 0.001);而骨连接蛋白显示出与体内胰腺癌细胞的生长呈负相关的趋势(p = 0.10)。在人类Suite2-007和大鼠AsML PDAC细胞与大鼠肝细胞的体外共培养模型中,在肿瘤细胞中发现OPN mRNA的表达明显增加。另外,用特定的反义寡核苷酸对骨桥蛋白的下调和用外源rh-骨粘连蛋白的治疗都与减少的细胞增殖有关。根据后者的发现,骨连接蛋白的下调与增殖增加有关。该证据支持骨桥蛋白的促肿瘤作用,并指出骨连接蛋白在PDAC中的抗肿瘤作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号